{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:14:26Z","timestamp":1773098066553,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is evidence of reduced SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. We hypothesized that tumor and treatment-related immunosuppression can be depicted in peripheral blood, and that immune profiling prior to vaccination can help predict immunogenicity. We performed a comprehensive immunological characterization of 83 hematological patients before vaccination and measured IgM, IgG, and IgA antibody response to four viral antigens at day +7 after second-dose COVID-19 vaccination using multidimensional and computational flow cytometry. Health care practitioners of similar age were the control group (<jats:italic>n<\/jats:italic>\u2009=\u2009102). Forty-four out of 59 immune cell types were significantly altered in patients; those with monoclonal gammopathies showed greater immunosuppression than patients with B-cell disorders and Hodgkin lymphoma. Immune dysregulation emerged before treatment, peaked while on-therapy, and did not return to normalcy after stopping treatment. We identified an immunotype that was significantly associated with poor antibody response and uncovered that the frequency of neutrophils, classical monocytes, CD4, and CD8 effector memory CD127low T cells, as well as naive CD21+ and IgM+D+ memory B cells, were independently associated with immunogenicity. Thus, we provide novel immune biomarkers to predict COVID-19 vaccine effectiveness in hematological patients, which are complementary to treatment-related factors and may help tailoring possible vaccine boosters.<\/jats:p>","DOI":"10.1038\/s41408-021-00594-1","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T12:16:55Z","timestamp":1639484215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies"],"prefix":"10.1038","volume":"11","author":[{"given":"Luis-Esteban","family":"Tamariz-Amador","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Martina","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9260-3025","authenticated-orcid":false,"given":"Anastasiia","family":"Zherniakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1395-5140","authenticated-orcid":false,"given":"Camila","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aintzane","family":"Zabaleta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leire","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1522-4504","authenticated-orcid":false,"given":"Cirino","family":"Botta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Antonia","family":"Fortu\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7227-1975","authenticated-orcid":false,"given":"Carlos","family":"Grande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Manubens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose-Maria","family":"Argui\u00f1ano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Perez-Persona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u00f1igo","family":"Olazabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itziar","family":"Oiartzabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Panizo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-8790","authenticated-orcid":false,"given":"Felipe","family":"Prosper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus F.","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8155-9185","authenticated-orcid":false,"given":"Esperanza","family":"Mart\u00edn-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Asociaci\u00f3n Vasco-Navarra de Hematolog\u00eda y Hemoterapia (ASOVASNA) Cooperative Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"594_CR1","unstructured":"Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907\u201318. https:\/\/pubmed.ncbi.nlm.nih.gov\/32473681\/"},{"key":"594_CR2","doi-asserted-by":"crossref","unstructured":"Wang QQ, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol. 2021;7:220\u20137. https:\/\/pubmed.ncbi.nlm.nih.gov\/33300956\/","DOI":"10.1001\/jamaoncol.2020.6178"},{"key":"594_CR3","doi-asserted-by":"crossref","unstructured":"Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, et al. Case fatality rate of cancer patients with COVID-19 in a New York Hospital system. Cancer Discov. 2020;10:935\u201341. https:\/\/pubmed.ncbi.nlm.nih.gov\/32357994\/","DOI":"10.1158\/2159-8290.CD-20-0516"},{"key":"594_CR4","doi-asserted-by":"crossref","unstructured":"Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26:1218\u201323. https:\/\/pubmed.ncbi.nlm.nih.gov\/32581323\/","DOI":"10.1038\/s41591-020-0979-0"},{"key":"594_CR5","doi-asserted-by":"crossref","unstructured":"Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;27:1280\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/34017137\/","DOI":"10.1038\/s41591-021-01386-7"},{"key":"594_CR6","unstructured":"Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021;32:787\u2013800. https:\/\/pubmed.ncbi.nlm.nih.gov\/33746047\/"},{"key":"594_CR7","doi-asserted-by":"crossref","unstructured":"Maia C, Mart\u00edn-S\u00e1nchez E, Garc\u00e9s JJ, de Cerio ALD, Inog\u00e9s S, Landecho MF, et al. Immunologic characterization of COVID-19 patients with hematological cancer. Haematologica. 2021;106:1457\u201360. https:\/\/pubmed.ncbi.nlm.nih.gov\/33327714\/","DOI":"10.3324\/haematol.2020.269878"},{"key":"594_CR8","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-S\u00e1nchez E, Garc\u00e9s JJ, Maia C, Inog\u00e9s S, L\u00f3pez-D\u00edaz de Cerio A, Carmona-Torre F, et al. Immunological biomarkers of fatal COVID-19: a study of 868 patients. Front Immunol. 2021;12. https:\/\/pubmed.ncbi.nlm.nih.gov\/34012444\/","DOI":"10.3389\/fimmu.2021.659018"},{"key":"594_CR9","doi-asserted-by":"crossref","unstructured":"Griffiths EA, Segal BH. Immune responses to COVID-19 vaccines in patients with cancer: promising results and a note of caution. Cancer Cell. 2021;39. https:\/\/pubmed.ncbi.nlm.nih.gov\/34242573\/","DOI":"10.1016\/j.ccell.2021.07.001"},{"key":"594_CR10","doi-asserted-by":"crossref","unstructured":"Abdul-Jawad S, Ba\u00f9 L, Alaguthurai T, del Molino del Barrio I, Laing AG, Hayday TS, et al. Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients. Cancer Cell. 2021;39:257\u2013.e6. https:\/\/pubmed.ncbi.nlm.nih.gov\/33476581\/","DOI":"10.1016\/j.ccell.2021.01.001"},{"key":"594_CR11","doi-asserted-by":"crossref","unstructured":"Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737\u201345. https:\/\/pubmed.ncbi.nlm.nih.gov\/32798473\/","DOI":"10.1016\/S2352-3026(20)30251-9"},{"key":"594_CR12","unstructured":"Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134\u201343. https:\/\/pubmed.ncbi.nlm.nih.gov\/32688395\/"},{"key":"594_CR13","doi-asserted-by":"crossref","unstructured":"Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set. Blood. 2020;136:3033\u201340. https:\/\/pubmed.ncbi.nlm.nih.gov\/33367546\/","DOI":"10.1182\/blood.2020008150"},{"key":"594_CR14","doi-asserted-by":"crossref","unstructured":"Marra A, Generali D, Zagami P, Cervoni V, Gandini S, Venturini S, et al. Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2. Ann Oncol. 2021;32:113\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/33098994\/","DOI":"10.1016\/j.annonc.2020.10.473"},{"key":"594_CR15","doi-asserted-by":"crossref","unstructured":"Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Di Marco M, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39:1091\u2013.e2. https:\/\/pubmed.ncbi.nlm.nih.gov\/34214473\/","DOI":"10.1016\/j.ccell.2021.06.009"},{"key":"594_CR16","doi-asserted-by":"crossref","unstructured":"Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39:1081\u2013.e2. https:\/\/pubmed.ncbi.nlm.nih.gov\/34133951\/","DOI":"10.1016\/j.ccell.2021.06.002"},{"key":"594_CR17","doi-asserted-by":"crossref","unstructured":"Agha M, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. Serv Heal Sci. 2021. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33851182%0Ahttp:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=PMC8043479","DOI":"10.1101\/2021.04.06.21254949"},{"key":"594_CR18","doi-asserted-by":"crossref","unstructured":"Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39:1031\u20133. https:\/\/pubmed.ncbi.nlm.nih.gov\/34331856\/","DOI":"10.1016\/j.ccell.2021.07.012"},{"key":"594_CR19","doi-asserted-by":"crossref","unstructured":"Passamonti F, Romano A, Salvini M, Merli F, Porta MGD, Bruna R, et al. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. Br J Haematol. 2021. https:\/\/pubmed.ncbi.nlm.nih.gov\/34272724\/","DOI":"10.1111\/bjh.17704"},{"key":"594_CR20","doi-asserted-by":"crossref","unstructured":"Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165\u201373. https:\/\/pubmed.ncbi.nlm.nih.gov\/33861303\/","DOI":"10.1182\/blood.2021011568"},{"key":"594_CR21","doi-asserted-by":"crossref","unstructured":"Parry H, McIlroy G, Bruton R, Ali M, Stephens C, Damery S, et al. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J. 2021;11:136. https:\/\/pubmed.ncbi.nlm.nih.gov\/34330895\/","DOI":"10.1038\/s41408-021-00528-x"},{"key":"594_CR22","doi-asserted-by":"crossref","unstructured":"Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell\u2013directed therapies. Blood. 2021;138:811\u20134. https:\/\/pubmed.ncbi.nlm.nih.gov\/34189565\/","DOI":"10.1182\/blood.2021012443"},{"key":"594_CR23","doi-asserted-by":"crossref","unstructured":"Lim SH, Campbell N, Johnson M, Joseph-Pietras D, Collins GP, O\u2019Callaghan A, et al. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. Lancet Haematol. 2021;8:e542\u20134. https:\/\/pubmed.ncbi.nlm.nih.gov\/34224667\/","DOI":"10.1016\/S2352-3026(21)00199-X"},{"key":"594_CR24","doi-asserted-by":"crossref","unstructured":"Terpos E, Trougakos IP, Gavriatopoulou M, Papassotiriou I, Sklirou AD, Ntanasis-Stathopoulos I, et al. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021;137:3674\u20136. https:\/\/pubmed.ncbi.nlm.nih.gov\/33861315\/","DOI":"10.1182\/blood.2021011904"},{"key":"594_CR25","doi-asserted-by":"crossref","unstructured":"Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021;11. https:\/\/pubmed.ncbi.nlm.nih.gov\/34341335\/","DOI":"10.1038\/s41408-021-00530-3"},{"key":"594_CR26","doi-asserted-by":"crossref","unstructured":"Stampfer SD, Goldwater MS, Jew S, Bujarski S, Regidor B, Daniely D, et al. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Leukemia. 2021. https:\/\/pubmed.ncbi.nlm.nih.gov\/34326466\/","DOI":"10.22541\/au.166879031.16384547\/v1"},{"key":"594_CR27","doi-asserted-by":"crossref","unstructured":"Avivi I, Balaban R, Shragai T, Sheffer G, Morales M, Aharon A, et al. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. Br J Haematol. 2021. https:\/\/pubmed.ncbi.nlm.nih.gov\/34196388\/","DOI":"10.1111\/bjh.17608"},{"key":"594_CR28","doi-asserted-by":"crossref","unstructured":"Van Oekelen O, Gleason CR, Agte S, Srivastava K, Beach KF, Aleman A, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021;39:1028\u201330. https:\/\/pubmed.ncbi.nlm.nih.gov\/34242572\/","DOI":"10.1016\/j.ccell.2021.06.014"},{"key":"594_CR29","doi-asserted-by":"crossref","unstructured":"Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. J Hematol Oncol. 2021;14. https:\/\/pubmed.ncbi.nlm.nih.gov\/34001183\/","DOI":"10.1186\/s13045-021-01090-6"},{"key":"594_CR30","doi-asserted-by":"crossref","unstructured":"Bird S, Panopoulou A, Shea RL, Tsui M, Saso R, Sud A, et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol. 2021;8:e389\u201392. https:\/\/pubmed.ncbi.nlm.nih.gov\/33887255\/","DOI":"10.1016\/S2352-3026(21)00110-1"},{"key":"594_CR31","doi-asserted-by":"crossref","unstructured":"C\u00e1ceres-Martell Y, Fern\u00e1ndez-Soto D, Campos-Silva C, Garc\u00eda-Cuesta EM, Casasnovas JM, Navas-Herrera D, et al. Single-reaction multi-antigen serological test for comprehensive evaluation of SARS-CoV-2 patients by flow cytometry. Eur J Immunol. 2021. https:\/\/pubmed.ncbi.nlm.nih.gov\/34358329\/","DOI":"10.1002\/EJI.202149319\/v2\/response1"},{"key":"594_CR32","doi-asserted-by":"crossref","unstructured":"Kalina T, Flores-Montero J, Van Der Velden VHJ, Martin-Ayuso M, B\u00f6ttcher S, Ritgen M, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986\u20132010. https:\/\/pubmed.ncbi.nlm.nih.gov\/22948490\/","DOI":"10.1038\/leu.2012.122"},{"key":"594_CR33","unstructured":"Botta C, Maia C, Garc\u00e9s J, Termini R, Perez C, Manrique I, et al. FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology. Blood Adv. 2021. https:\/\/pubmed.ncbi.nlm.nih.gov\/34587246\/"},{"key":"594_CR34","doi-asserted-by":"crossref","unstructured":"Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Br\u00fcggen MC, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy Eur J Allergy Clin Immunol. 2020;75:1564\u201381. https:\/\/pubmed.ncbi.nlm.nih.gov\/32396996\/","DOI":"10.1111\/all.14364"},{"key":"594_CR35","unstructured":"Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397:1725\u201335. https:\/\/pubmed.ncbi.nlm.nih.gov\/33901423\/"},{"key":"594_CR36","doi-asserted-by":"crossref","unstructured":"Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among Health Care Workers. J Am Med Assoc. 2021;325:2457\u201365. https:\/\/pubmed.ncbi.nlm.nih.gov\/33956048\/","DOI":"10.1001\/jama.2021.7152"},{"key":"594_CR37","doi-asserted-by":"publisher","first-page":"e1376","DOI":"10.1093\/cid\/ciab361","volume":"73","author":"MD Swift","year":"2021","unstructured":"Swift MD, Breeher LE, Tande AJ, Tommaso CP, Hainy CM, Chu H, et al. Effectiveness of messenger RNA coronavirus disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a cohort of healthcare personnel. Clin Infect Dis. 2021;73:e1376\u20139.","journal-title":"Clin Infect Dis"},{"key":"594_CR38","doi-asserted-by":"crossref","unstructured":"Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881\u201392. https:\/\/pubmed.ncbi.nlm.nih.gov\/33113551\/","DOI":"10.1182\/blood.2020008824"},{"key":"594_CR39","doi-asserted-by":"crossref","unstructured":"Malard F, Gaugler B, Gozlan J, Bouquet L, Fofana D, Siblany L, et al. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer J. 2021;11. https:\/\/pubmed.ncbi.nlm.nih.gov\/34376633\/","DOI":"10.1038\/s41408-021-00534-z"},{"key":"594_CR40","doi-asserted-by":"crossref","unstructured":"Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21:626\u201336. https:\/\/pubmed.ncbi.nlm.nih.gov\/34373623\/","DOI":"10.1038\/s41577-021-00592-1"},{"key":"594_CR41","doi-asserted-by":"crossref","unstructured":"Sun L, Warner JL, Parikh RB. Immune responses to SARS-CoV-2 among patients with cancer: what can seropositivity tell us? JAMA Oncol. 2021;7:1123\u20135. https:\/\/pubmed.ncbi.nlm.nih.gov\/34047766\/","DOI":"10.1001\/jamaoncol.2021.2096"},{"key":"594_CR42","doi-asserted-by":"crossref","unstructured":"Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA. 2021;326:1533\u20135. https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2783797","DOI":"10.1001\/jama.2021.15125"},{"key":"594_CR43","doi-asserted-by":"crossref","unstructured":"Monin L, Laing AG, Mu\u00f1oz-Ruiz M, McKenzie DR, del Molino del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22:765\u201378. https:\/\/pubmed.ncbi.nlm.nih.gov\/33930323\/","DOI":"10.1016\/S1470-2045(21)00213-8"},{"key":"594_CR44","doi-asserted-by":"crossref","unstructured":"Ehmsen S, Asmussen A, Jeppesen SS, Nilsson AC, \u00d8sterlev S, Vestergaard H, et al. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2021;39:1034\u20136. https:\/\/pubmed.ncbi.nlm.nih.gov\/34348121\/","DOI":"10.1016\/j.ccell.2021.07.016"},{"key":"594_CR45","doi-asserted-by":"crossref","unstructured":"Lederer K, Casta\u00f1o D, G\u00f3mez Atria D, Oguin TH, Wang S, Manzoni TB, et al. SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation. Immunity. 2020;53:1281\u2013.e5. https:\/\/pubmed.ncbi.nlm.nih.gov\/33296685\/","DOI":"10.1016\/j.immuni.2020.11.009"},{"key":"594_CR46","doi-asserted-by":"crossref","unstructured":"Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O, et al. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity. 2021;54:2133\u2013.e3. https:\/\/pubmed.ncbi.nlm.nih.gov\/34453880\/","DOI":"10.1016\/j.immuni.2021.08.001"},{"key":"594_CR47","doi-asserted-by":"crossref","unstructured":"Ghandili S, Sch\u00f6nlein M, L\u00fctgehetmann M, Schulze Zur Wiesch J, Becher H, Bokemeyer C, et al. Post\u2010vaccination anti\u2010sars\u2010cov\u20102\u2010antibody response in patients with multiple myeloma correlates with low cd19+ b\u2010lymphocyte count and anti\u2010cd38 treatment. Cancers (Basel). 2021;13.","DOI":"10.3390\/cancers13153800"},{"key":"594_CR48","doi-asserted-by":"crossref","unstructured":"Perez C, Botta C, Zabaleta A, Puig N, Cedena MT, Goicoechea I, et al. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood. 2020;136:199\u2013209. https:\/\/pubmed.ncbi.nlm.nih.gov\/32325491\/","DOI":"10.1182\/blood.2019004537"},{"key":"594_CR49","doi-asserted-by":"crossref","unstructured":"Van Dongen JJM, Van Der Burg M, Kalina T, Perez-Andres M, Mejstrikova E, Vlkova M, et al. EuroFlow-based flowcytometric diagnostic screening and classification of primary immunodeficiencies of the lymphoid system. Front Immunol 2019;10. https:\/\/pubmed.ncbi.nlm.nih.gov\/31263462\/","DOI":"10.3389\/fimmu.2019.01271"},{"key":"594_CR50","unstructured":"Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science (80). 2021;372:1418\u201323. https:\/\/pubmed.ncbi.nlm.nih.gov\/33931567\/"},{"key":"594_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.abi6950","volume":"6","author":"RR Goel","year":"2021","unstructured":"Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct antibody and memory B cell responses in SARSCoV-2 na\u00efve and recovered individuals following mRNA vaccination. Sci Immunol. 2021;6:1\u201319.","journal-title":"Sci Immunol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00594-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00594-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00594-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:28:04Z","timestamp":1669919284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00594-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":51,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["594"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00594-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"assertion":[{"value":"23 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"202"}}